OnKure Therapeutics Secures $150 Million in Private Placement for Oncology Pipeline

OnKure Therapeutics (OKUR) has announced a securities purchase agreement for a private placement, raising approximately $150 million. The financing round was led by Access Biotechnology, with significant participation from both new and existing institutional investors. The company plans to utilize the net proceeds to advance its clinical pipeline, specifically focusing on next-generation PI3Kα pan-mutant selective inhibitors. These therapies target breast cancer and vascular anomalies, with Investigational New Drug (IND) filings projected for the first half of 2027. The oversubscribed nature of the placement underscores strong investor confidence in the company's oncology research and long-term clinical milestones. Additionally, Liam Ratcliffe will join the company's Board of Directors as part of the financing agreement.

Sources:globenewswire.comstocktitan.netstreetinsider.cominvesting.com